Loading clinical trials...

Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients

A Phase 3, Multi-Center, Single-Arm, Open-Label Study For The Safety And Efficacy Of Mistletoe Extract (AbnobaViscum® Injection) In Malignant Pleural Effusions

NCT02191540•Abnoba Korea

View on ClinicalTrials.gov

Summary

Phase 3, non-randomized, Multicenter, single arm study to assess efficacy and safety of Abnoba viscum F 20mg in patients with malignant pleural effusion

Eligibility

Age

20 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subject who need the pleurodesis among subjects diagnosed with a mlignant pleural effusion
•Full lung expansion must be achieved within 12 to 24 hours after drainage
•Expected survival time of at least 2 months
•Subject who score 50 or more on the Karnofsky Performance Scale

Exclusion Criteria

•Subjects with previous attempts at pleurodesis with sclerosing agent
•Subjects with trapped lung or bronchial obstruction
•Subjects with adverse drug response to mistletoe agents
•Subjects who have participated in another clinical study other than the present study
•Subjects who is taking immune-suppressive agents
•Subjects with medical and psychiatric contraindications for the study drug
•Subjects who are not allowed to participate in the study by legal requirement
•Subjects who are not allowed to participate in the study by the Investigator's discretion

Locations (3)

Busan University Hospital

Busan, Busan, South Korea

Chonnam National University Hwasun hospital

Hwasun Gun, Jeollanam-do, South Korea

Ulsan University Hospital

Ulsan, Ulsan, South Korea

Key Dates

Start Date

January 1, 2011

Primary Completion Date

January 1, 2013

Completion Date

May 1, 2013

Last Updated

July 23, 2014

Enrollment

ACTUAL participants

Conditions

Malignant Pleural Effusion

Interventions

Abnoba Viscum F 20mg

DRUG

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

NCT06016179

Malignant Pleural EffusionMalignant Ascites

View study

RECRUITINGNA

Feasibility of Ambulatory Talc. Pleurodesis

NCT06682936

Malignant Pleural EffusionMalignancy+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 23, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients

Inclusion Criteria

Exclusion Criteria

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Feasibility of Ambulatory Talc. Pleurodesis

OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

Cytological Examination of Malignant Pleural Effusion in Breast Cancer